AZ-WORLD-VIEW
17.3.2022 15:46:04 CET | Business Wire | Press release
World View , an expert in stratospheric exploration on a mission to help spaceflight participants rediscover Earth, today announces the debut of its spaceflight capsule prototype. The announcement marks another exciting milestone for the company, following recent news of its entry into the space tourism sector and appointment of President of Tourism and Exploration, Dale Hipsh.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220317005669/en/
Spaceflight participants eagerly awaiting the launch of commercial flights beginning in 2024 are provided a first-look at the distinctive World View experience, from onboard amenities and design touches to the superior hospitality and life-changing perspectives enjoyed throughout the journey.
“Unveiling our space capsule prototype is a pivotal moment for the company as we continue to prepare for our first launch from the Grand Canyon in just two short years,” said Ryan Hartman, President and Chief Executive Officer of World View. “We are thrilled to partner with leaders in aerospace design and engineering to bring our vision to life and ensure spaceflight participants enjoy a truly transformative experience.”
The exterior of the World View space capsule is shaped like a faceted hexagon with softened edges and a pearlescent white finish, which offers thermal management properties but also enhances the geometric detailing and curves. It boasts large elliptical windows that measure approximately 6.5 feet wide x 4.5 feet high, framing impressive views of the Earth’s curvature and its natural wonders. When seats are in a reclined position, the sky window on top of the capsule provides passengers an exciting line of sight to the balloon lifting them as well as constellations upon reaching float altitude. The central ceiling pelmet also includes a mood wash light that changes in accordance with the stage in flight to provide optimal viewing out of the capsule’s windows.
The capsule is climate-controlled and pressurized with an entire interior designed to maximize space, allowing spaceflight participants to move freely and comfortably about the capsule. The color palette, materials and finishes create an environment of calm, with clean lines, soft tones and clever concealment of functional elements–such as lavatory and galley entrances–so the focus remains on the stunning vistas and sights outside. Aligned with World View’s commitment to sustainability, great care is being taken to ensure materials are sourced from sustainable vendors whenever possible and options for re-use or recycling are being thoroughly explored.
Luxurious, ergonomic seating for eight passengers is configured in pairs, with an additional pair designated for crew members. Amenities including a cocktail table, graphical user interface (GUI) screen (providing educational materials and engaging activities), central console, personal storage and beverage holder, are at spaceflight participants’ fingertips to ensure that no moment of the journey is missed. Each capsule is outfitted with an onboard telescope to maximize viewing throughout the journey. Spaceflight participants will also enjoy gourmet custom dining options and top-shelf libations throughout their flight and each capsule will be equipped with streaming and mobile communication capabilities to stay in touch with loved ones back on Earth.
Projected lift off is scheduled before dawn, providing participants a front row seat to the sunrise on most flights. Along the journey, passengers will take in the curvature of the Earth, thin blue line of the atmosphere, vast darkness of space and constellations. Without the typical turbulence found on an airplane flight, spaceflight participants will be able to stand and move about the craft shortly after launch. The onboard crew, including one pilot and one concierge, serve as both Earth and space guides, cross-trained in flight operations, hospitality and medical support.
World View’s space tourism program begins launching commercial flights in 2024 with voyages taking off from natural and man-made wonders such as the Grand Canyon and Great Barrier Reef. Flights will lift passengers in a zero-pressure stratospheric balloon and pressurized space capsule to 100,000 feet altitude, nearly 23 miles above Earth, for an unparalleled experience that will last six to eight hours. Participants will fully experience and immerse themselves in the beauty, fragility, history and importance of the areas surrounding each location and of the Earth itself.
Design elements and engineering considerations continue to be refined. Further information on World View available at worldview.space .
ABOUT WORLD VIEW
World View is the leading stratospheric exploration company on a mission to inspire the global community to rediscover Earth. Through both its legacy Stratollite imaging and newly launched space tourism and exploration businesses, World View is working to ensure its ultimate objective: honor the planet so that future generations will feel blessed to call it home. For more information, visit worldview.space .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220317005669/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom